RYTM

NASDAQBOSTON, MA

RHYTHM PHARMACEUTICALS, INC.

Rhythm Pharmaceuticals develops drugs targeting rare genetic obesity and related metabolic disorders, primarily focusing on the MC4R pathway. The company's lead product, setmelanotide (IMCIVREE), is already commercialized, while other candidates like bivamelagon and RM-718 are in clinical development across Phase 1 to Phase 3 trials.

Price history not yet available for RYTM.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.